Keytruda Surpasses Comirnaty to Become World’s Top-Selling Drug in 2023
February 2, 2024
Merck’s Keytruda has emerged as the world’s top-selling drug in 2023, with sales reaching $25 billion, surpassing Pfizer and BioNTech’s Comirnaty, which led the previous two years. Keytruda’s success marks a significant milestone, outperforming long-time leaders like AbbVie’s Humira and Pfizer’s Lipitor. The PD-1 inhibitor’s growth has been consistent since its launch, with substantial sales increases each year, including a notable jump from $7.2 billion in its fourth year. In 2023, Keytruda’s sales constituted 41.6% of Merck’s revenue, bolstered by its expansion into new treatment areas and strong demand for metastatic disease treatments. Despite its dominance, Keytruda faces potential competition from Novo Nordisk’s semaglutide-based therapies, rapidly gaining market share.
To read more, click here.
[Source: Fierce Pharma, February 1st, 2024]
